Back to results
US 10,300,046 B2Granted
Pharmaceutical compositions
AssigneeMelinta Subsidiary Corp.
InventorDanping Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions useful for administration for treating, preventing, or reducing the risk of microbial infections.
Claims13
A pharmaceutical composition comprising prior to mixing:
- (a) radezolid or a pharmaceutically acceptable salt, ester, or prodrug thereof;
- (b) a hydroxypropylmethyl cellulose polymer;
- (c) croscarmellose sodium;
- (d) a lubricant selected from colloidal silicon dioxide, magnesium stearate, and mixtures thereof;
- (e) microcrystalline cellulose;
- and
- (f) a filler selected from lactose monohydrate, dicalciumphosphate, and mixtures thereof;
- wherein the pharmaceutical composition comprises a physical mixture.
5 more elements
A pharmaceutical composition comprising:
- (a) radezolid or a pharmaceutically acceptable salt, ester, or prodrug thereof;
- (b) a hydroxypropylmethyl cellulose polymer;
- (c) croscarmellose sodium;
- (d) a lubricant selected from colloidal silicon dioxide, magnesium stearate, and mixtures thereof;
- and
- (e) a filler selected from lactose monohydrate, dicalciumphosphate, and mixtures thereof;
- wherein the pharmaceutical composition comprises a physical mixture.
4 more elements
A pharmaceutical composition comprising:
- Percent by
- Ingredients
- Weight
- Intra Granular
- Radezolid hydrochloride
- 20.31%
- (amount as hydrochloride salt)
- HPMCAS-M Spray Dried
- 13.28%
- HPMCAS-H Spray Dried
- 13.28%
- Croscarmellose Sodium
- 4.00%
- Microcrystalline cellulose
- 11.60%
- Lactose monohydrate
- 11.60%
- Colloidal silicon dioxide
- 0.75%
- Magnesium Stearate
- 0.19%
- Extra Granular
- Croscarmellose Sodium
- 1.50%
- Di-Cal Phosphate (DC Grade)
- 23.38%
- Colloidal silicon dioxide
- 0.06%
- Magnesium Stearate
- 0.06%
- wherein the pharmaceutical composition comprises a physical mixture.
28 more elements
Dependencies are inferred from the claim text.